glp-1/fgf21 agonist boehringer Safety and efficacy of dual HEC88473 in MASLD and T2DM: A randomized, double-blind, placebo-controlled study MASH field still hot as
Description
Available from: 147
Strategies to correct the incretin defects in patients with type 2 diabetes include replacement of GLP-1 with a long-acting analog that resists degradation and development of drugs that inhibit the enzyme DPP-4, which breaks down GLP-1
These medications have increased in popularity over the past few years, and there is a lot of interest especially in women who are wanting to lost weight postpartum
2023 Jan 11;15(1)
Results from a prospective cohort study
J.KimJ.et al (2021)
